Abstract
15550 Background: High-grade neuroendocrine carcinoma (HGNEC) are rare but aggressive characterized by high mitotic rate. Metastatic disease is incurable. Systemic treatments for HGNEC have been extrapolated from those for small cell lung carcinoma. Effective regimens for HGNEC alone have not been established. The combination of Irinotecan (I), and Cisplatin (P) was evaluated among patients with metastatic or unresectable HGNEC. Methods: Eligible patients were histologically confirmed HGNEC, previously untreated with unresectable or metastatic, measurable disease, adequate bone marrow, renal function, hepatic function and Zubrod performance status < 2. Patients were treated with IP (I 65mg/m2 IV D1+8 and P 25mg/m2 D1+8, every 21 days cycle). Primary endpoints were objective responses and toxicity profile. Response assessed by RECIST every 3 cycles. Dose modification of both drugs was allowed for grade 3/4 toxicities. Results: 20 patients were enrolled from 2003 until 2007, with 19 were evaluable for respo...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
